Global Allergic Rhinitis Drugs Market 2018-2028 - Visiongain Report

Wednesday, August 29, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, August 29, 2018 /PRNewswire/ --

Oral Antihistamines, Intranasal Corticosteroids,

Intranasal Antihistamines, Immunotherapy and Vaccines

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.3% in the first half of the forecast period. The market is estimated at $12.2bn

in 2017 and $14.3bn in 2022.

     (Photo: )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 256-page report you will receive 97 tables and 100 figures- all unavailable elsewhere.

The 256-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Allergic Rhinitis Drugs Market forecasts from 2018-2028

• Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2028 for the following submarkets: • Intranasal Antihistamines • Intranasal Corticosteroids • Oral Antihistamines • Immunotherapy and Vaccines

• How will leading allergic rhinitis drugs perform to 2028 at world level? Our study forecasts individual revenues of these 27 products: • Patanase • Astepro • Astelin • Dymista • Nasonex • Avamys • Veramyst • Flixonase • Rhinocort • Omnaris • Nasacort • Beconase • Qnasl • Zetonna • Allegra • Zyrtec • Claritin • Xyzal • Allelock • Clarinex • Ebastel • Talion • Staloral • Alutard SQ • Grazax • Ragwitek • Generic Azelastine

• This report provides individual revenue forecasts to 2028 for these regional and national markets: • US • EU5 - Germany, UK, France, Italy and Spain China Japan India Russia Brazil • Rest of the World

Each national market is further segmented by submarket. 

• Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market: • GlaxoSmithKline (GSK) • Merck & Co • Sanofi • Johnson & Johnson • ALK-Abello • UCB • Kyowo Hako Kirin • Stallergenes Greer

• This report discusses the trends and development in the allergic rhinitis pipeline

• Our study discusses strengths, weaknesses, opportunities and threats as well as porter's five forces analysis of the global allergic rhinitis drugs market

Visiongain's study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Buy our report today Global Allergic Rhinitis Drugs Market 2018-2028: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

To request a report overview of this report please contact Sara Peerun at or refer to our website :

ActoGeniX Adamis Pharmaceuticals ALK- Abelló Allergy Medical UK Allergy Therapeutics Almirall Altana Pharma (Nycomed) Anergis Apotex AstraZeneca Atopix Therapeutics Barr Laboratories Bausch & Lomb Belcher Pharmaceuticals Biotech Tools  Catalent Pharma Solutions Celsus Therapeutics Dainippon Sumitomo DBV Technologies  Dr Reddy's Laboratories Eddingpharm Eleventa Genzyme (Sanofi) GlaxoSmithKline Greer Laboratories Hisamitsu Pharmaceutical Co Hoechst AG Human Genome Sciences Intas Pharmaceuticals Johnson & Johnson Keldman Healthcare Kyowa Hakko Kirin Leti Pharma (Laboratorios Leti) Lupin Pharmaceuticals Meda Pharma Medpointe Inc (Meda Pharma) Merck & Co Mitsubishi Tanabe Pharma Mylan Nippon Paper Group Novartis Omega Pharma Perrigo Pfizer ProStrakan (Kyowa Hakko Kirin) Reckitt Benckiser Roxane Laboratories (Boehringer Ingelheim) Sanofi  Schering-Plough (Merck) Shionogi & Co Ltd Stallergenes Sun Pharmaceuticals Sunovion Pharmaceuticals (Dainippon Sumitomo) Takeda Teva Pharmaceuticals Trimel Pharmaceuticals Ube Industries UCB ViiV Healthcare Wockhardt Ziarco Pharma

To see a report overview please e-mail Sara Peerun on

SOURCE Visiongain

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store